Source:http://linkedlifedata.com/resource/pubmed/id/10650856
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
2000-2-8
|
| pubmed:abstractText |
To evaluate the role of inherited thrombophilia in the development of central venous line (CVL)-related thrombosis, the following parameters were determined in 77 pediatric-oncologic patients with CVL: activated protein C (APC)-ratio, factor V (FV) G1691A and prothrombin G20210A mutation, protein C, protein S, antithrombin, coagulation factor XII, lipoprotein (a) and homocysteine. An inherited prothrombotic risk factor was found in 17 patients (23%). Four out of 14 patients with a single detect (hyperlipoproteinemia, heterozygous FV G1691A and prothrombin G20210A mutation, protein C deficiency type I) and all three patients with combined defects (heterozygous FV G1691A mutation combined with heterozygous prothrombin G20210A variant, protein S deficiency or hyperlipoproteinemia) suffered from CVL-related thrombosis. In 11 out of 77 patients (14%) a CVL-related thrombosis was detected. In 2 children thrombosis occurred a few days after asparaginase therapy and in another three thrombosis was associated with CVL-related septicemia caused by Staphylococcus epidermidis. After removal of CVL, thrombosis was detected in 5 children, in 2 without clinical symptoms but in the presence of inherited prothrombotic risk factors. CONCLUSION: The present study demonstrates the clinical importance of CVL in combination with inherited thrombophilia in the development of thrombosis in pediatric-oncologic patients. Before or shortly after insertion of CVL, patients should be tested for the presence of factor V G1691A mutation, prothrombin G20210A variant and increased lipoprotein (a) values.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0340-6199
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
158 Suppl 3
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
S147-50
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:10650856-Adolescent,
pubmed-meshheading:10650856-Catheterization, Central Venous,
pubmed-meshheading:10650856-Child,
pubmed-meshheading:10650856-Child, Preschool,
pubmed-meshheading:10650856-Factor V,
pubmed-meshheading:10650856-Female,
pubmed-meshheading:10650856-Genetic Predisposition to Disease,
pubmed-meshheading:10650856-Germany,
pubmed-meshheading:10650856-Humans,
pubmed-meshheading:10650856-Infant,
pubmed-meshheading:10650856-Infant, Newborn,
pubmed-meshheading:10650856-Lipoprotein(a),
pubmed-meshheading:10650856-Male,
pubmed-meshheading:10650856-Neoplasms,
pubmed-meshheading:10650856-Prothrombin,
pubmed-meshheading:10650856-Risk Factors,
pubmed-meshheading:10650856-Thrombophilia,
pubmed-meshheading:10650856-Venous Thrombosis
|
| pubmed:year |
1999
|
| pubmed:articleTitle |
Clinical importance of prothrombotic risk factors in pediatric patients with malignancy--impact of central venous lines.
|
| pubmed:affiliation |
Department of Pediatrics, Medical Faculty of Technical University, Dresden, Germany.
|
| pubmed:publicationType |
Journal Article
|